JP4993852B2 - ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 - Google Patents

ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 Download PDF

Info

Publication number
JP4993852B2
JP4993852B2 JP2004271927A JP2004271927A JP4993852B2 JP 4993852 B2 JP4993852 B2 JP 4993852B2 JP 2004271927 A JP2004271927 A JP 2004271927A JP 2004271927 A JP2004271927 A JP 2004271927A JP 4993852 B2 JP4993852 B2 JP 4993852B2
Authority
JP
Japan
Prior art keywords
acid
genus
arachidonic acid
stress
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004271927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006083134A (ja
JP2006083134A5 (enExample
Inventor
義之 石倉
学 榊原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004271927A priority Critical patent/JP4993852B2/ja
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Priority to AU2005283697A priority patent/AU2005283697B9/en
Priority to US11/663,076 priority patent/US8202907B2/en
Priority to PCT/JP2005/005623 priority patent/WO2006030553A1/en
Priority to CA2579807A priority patent/CA2579807C/en
Publication of JP2006083134A publication Critical patent/JP2006083134A/ja
Publication of JP2006083134A5 publication Critical patent/JP2006083134A5/ja
Priority to US13/465,546 priority patent/US8367729B2/en
Application granted granted Critical
Publication of JP4993852B2 publication Critical patent/JP4993852B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004271927A 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 Expired - Fee Related JP4993852B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004271927A JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US11/663,076 US8202907B2 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
PCT/JP2005/005623 WO2006030553A1 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
CA2579807A CA2579807C (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
AU2005283697A AU2005283697B9 (en) 2004-09-17 2005-03-18 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US13/465,546 US8367729B2 (en) 2004-09-17 2012-05-07 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004271927A JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物

Publications (3)

Publication Number Publication Date
JP2006083134A JP2006083134A (ja) 2006-03-30
JP2006083134A5 JP2006083134A5 (enExample) 2007-11-01
JP4993852B2 true JP4993852B2 (ja) 2012-08-08

Family

ID=34963492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004271927A Expired - Fee Related JP4993852B2 (ja) 2004-09-17 2004-09-17 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物

Country Status (5)

Country Link
US (2) US8202907B2 (enExample)
JP (1) JP4993852B2 (enExample)
AU (1) AU2005283697B9 (enExample)
CA (1) CA2579807C (enExample)
WO (1) WO2006030553A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
AU2007312216B2 (en) * 2006-10-19 2011-03-31 Nestec S.A. Long-term feed - cancer patient
KR101430214B1 (ko) * 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
LT2343982T (lt) 2008-09-17 2017-07-25 Chiasma Inc. Farmacinės kompozicijos ir susiję pateikimo būdai
WO2013002404A1 (ja) 2011-06-29 2013-01-03 日本水産株式会社 恐怖記憶の軽減方法
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1112820A (en) 1967-04-28 1968-05-08 Standard Telephones Cables Ltd Improvements in or relating to electrical storage systems
US4668704A (en) 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
AU693450B2 (en) 1993-06-09 1998-07-02 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
DK0784437T3 (da) 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
JP4034370B2 (ja) 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
DE69718455T2 (de) 1997-07-22 2003-04-30 Societe Des Produits Nestle S.A., Vevey Lipidzusammensetzung für Säuglingsnährpräparat und Herstellungsverfahren
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
DE69935995T3 (de) 1998-10-15 2011-02-10 Dsm Ip Assets B.V. Polyungesättigen fettsäuren nährungsergänzung
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
AU2001269375A1 (en) 2000-05-08 2001-11-20 Forskarpatent I Syd Ab Anandamide and structurally related lipids as vanilloid receptor modulators
US20020077355A1 (en) 2000-05-30 2002-06-20 Liao James K. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
ES2227220T3 (es) 2000-06-23 2005-04-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - inhibidor de factor de necrosis tumoral alfa y neuroprotector cerebral en traumatismo craneoencefalico cerrado.
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
AU2001292586A1 (en) 2000-09-07 2002-03-22 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
ES2324640T3 (es) 2001-03-09 2009-08-12 Societe Des Produits Nestle S.A. Aceite que contiene un o unos acido(s) graso(s) poliin-saturado(s) de cadena larga resultante de una biomasa, procedimiento de preparacion, alimento, composicion nutricional, cosmetica o farmaceutica que lo contiene.
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
ES2386841T3 (es) 2001-06-18 2012-09-03 Neptune Technologies & Bioressources Inc. Extractos de krill para la prevención y/o el tratamiento de enfermedades cardiovasculares
CN100523206C (zh) 2001-07-02 2009-08-05 三得利株式会社 含有含多不饱和脂肪酸的甘油三酯的油或脂肪的生产方法
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
CA2456034A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
WO2004024930A2 (en) 2002-09-13 2004-03-25 Suntory Limited Process for production of transesterified oils/fats or triglycerides
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
US20060057185A1 (en) 2002-09-24 2006-03-16 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
EP1542688A4 (en) * 2002-09-26 2010-06-02 3M Innovative Properties Co 1H-imidazo dimers
EP1605930B1 (en) 2003-03-27 2020-06-03 Suntory Holdings Limited Use of arachidonic acid for normalization of infradian rhythm
CN1774265A (zh) 2003-04-18 2006-05-17 协和发酵工业株式会社 神经再生药
WO2005018632A1 (en) 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20090215896A1 (en) 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Also Published As

Publication number Publication date
AU2005283697A1 (en) 2006-03-23
US20120220660A1 (en) 2012-08-30
WO2006030553A1 (en) 2006-03-23
CA2579807A1 (en) 2006-03-23
US8367729B2 (en) 2013-02-05
AU2005283697B2 (en) 2011-12-22
JP2006083134A (ja) 2006-03-30
US20070254954A1 (en) 2007-11-01
AU2005283697B9 (en) 2012-09-06
US8202907B2 (en) 2012-06-19
CA2579807C (en) 2013-05-28

Similar Documents

Publication Publication Date Title
US8367729B2 (en) Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
JP4771697B2 (ja) 認知能力の正常応答の低下予防、改善又は向上作用を有する組成物
JP2003048831A (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU2005283696B2 (en) Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases
JP4633048B2 (ja) 日内リズム正常化組成物
JP2007008863A (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP4522075B2 (ja) 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP5496163B2 (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2009219500A (ja) 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120410

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120508

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150518

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4993852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees